Sustained release metoprolol formulations
First Claim
Patent Images
1. A sustained release oral solid dosage form comprising:
- a sustained release matrix comprising from about 12.5 to about 400 mg of metoprolol tartrate and a sustained release excipient;
said oral dosage form providing a mean Cmax of metoprolol from about 10 ng/ml to about 40 ng/ml when the dosage form contains 100 mg metoprolol tartrate;
said dosage form providing a therapeutic effect for about 24 hours after oral administration.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a sustained release oral dosage forms containing a therapeutically effective amount of metoprolol tartrate, methods of preparing such formulations, and to methods of treatment utilizing such formulations.
-
Citations
79 Claims
-
1. A sustained release oral solid dosage form comprising:
-
a sustained release matrix comprising from about 12.5 to about 400 mg of metoprolol tartrate and a sustained release excipient;
said oral dosage form providing a mean Cmax of metoprolol from about 10 ng/ml to about 40 ng/ml when the dosage form contains 100 mg metoprolol tartrate;
said dosage form providing a therapeutic effect for about 24 hours after oral administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
-
23. A sustained release oral solid dosage form comprising:
-
a sustained release matrix comprising from about 12.5 to about 400 mg metoprolol tartrate and a sustained release excipient;
said oral dosage form providing a mean Cmax at steady state of metoprolol from about 4 ng/ml to about 20 ng/ml when the dosage form contains 25 mg metoprolol tartrate;
said dosage form providing a therapeutic effect for about 24 hours after oral administration. - View Dependent Claims (24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)
-
-
40. A sustained release oral solid dosage form comprising:
a sustained release matrix comprising from about 12.5 mg to about 400 mg of metoprolol tartrate and a sustained release excipient;
said oral dosage form providing a mean Cmax at steady state of metoprolol from about 5 ng/ml to about 30 ng/ml when the dosage form contains 50 mg metoprolol tartrate;
said dosage form providing a therapeutic effect for about 24 hours after oral administration.
-
41. A sustained release oral dosage form comprising:
metoprolol tartrate in an amount of from about 12.5 mg to about 400 mg dispersed in a matrix comprising (i) a gelling agent said gelling agent in an amount of from about 10% to about 60% by weight of the dosage form, (ii) an inert pharmaceutical diluent in an amount of from about 5% to about 40% by weight of the dosage form, and (iii) an ionizable gel strength enhancing agent in an amount of from about 0.5% to about 16% by weight of the dosage form;
a hydrophobic coating coated over said matrix in an amount of from about 1% to about 20% by weight of the dosage form;
said dosage form providing for a sustained release of said metoprolol tartrate suitable for once a day administration.- View Dependent Claims (42, 43, 44)
-
45. A sustained release oral dosage form comprising:
-
a matrix comprising metoprolol tartrate in an amount of from about 12.5 mg to about 400 mg dispersed in a sustained release excipient comprising (i) locust bean gum in an amount of 5% to about 30% by weight of the oral dosage form and (ii) xanthan gum in an amount from about 5% to about 30% by weight of the oral dosage form, (iii) mannitol in an amount of from about 5% to about 40% by weight of the oral dosage form, and (iv) calcium sulfate dihydrate in an amount of about 0.5% to about 16% by weight of the oral dosage form; and
a hydrophobic coating coated over said matrix in an amount of from about 1% to about 20% by weight of the oral dosage form;
said dosage form providing for a sustained release of said metoprolol tartrate suitable for once-a-day administration.
-
-
46. A sustained release tablet formulation comprising:
-
a matrix core composition comprising (a) metoprolol tartrate in an amount of from about 12.5 mg to about 400 mg;
(b) a cellulose derivative selected from the group consisting of an alkylcellulose, hydroxyalkylcellulose, hydroxypropylalkylcellulose, or mixtures thereof; and
(c) a sustained release excipient comprising a gelling agent in an amount of about 10% to about 60% by weight of the formulation;
an inert diluent in an amount of from about 5% to about 40% by weight of the formulation; and
an ionizable gel strength enhancing agent in an amount of from about 0.5% to about 16% by weight of the formulation; and
a coating over said core comprising (a) a hydrophobic material in an amount of from about 2% to about 15% by weight of the formulation;
said formulation providing for a sustained release of said metoprolol tartrate suitable for once-a-day administration. - View Dependent Claims (47, 48, 49, 50)
-
-
51. A sustained release excipient for the sustained release of an active agent comprising from about 20% to about 60% of a gelling agent by weight of said sustained release excipient, said gelling agent consisting of a heteropolysaccharide gum and a homopolysaccharide gum;
- from about 1% to about 20% of an ionizable gel strength enhancing agent by weight of said sustained release excipient; and
from about 6% to about 60% of mannitol by weight of the sustained release excipient. - View Dependent Claims (52, 53, 54, 55, 56)
- from about 1% to about 20% of an ionizable gel strength enhancing agent by weight of said sustained release excipient; and
-
57. A method of treating a patient with hypertension comprising:
administering to said patient a sustained release oral dosage form comprising a sustained release matrix comprising from about 12.5 to about 400 mg of metoprolol tartrate and a sustained release excipient;
said oral dosage form providing a mean Cmax of metoprolol from about 10 ng/ml to about 40 ng/ml when the dosage form contains 100 mg metoprolol tartrate;
said dosage form providing a therapeutic effect for about 24 hours after oral administration.- View Dependent Claims (58)
-
59. A method of reducing blood pressure comprising
administering to a human patient a sustained release oral solid dosage form comprising a sustained release matrix comprising about 12.5 to about 400 mg of metoprolol tartrate and a sustained release excipient; - said oral dosage form providing a mean Cmax of metoprolol from about 10 ng/ml to about 40 ng/ml when the dosage form contains 100 mg metoprolol tartrate, said dosage form providing a therapeutic effect for about 24 hours after oral administration.
-
60. A method of providing cardioselective antihypertensive therapy to a human patient comprising administering to said patient a sustained release oral dosage form comprising a sustained release matrix comprising about 12.5 to about 400 mg of metoprolol tartrate and a sustained release excipient;
- said oral dosage form providing a mean Cmax of metoprolol from about 10 ng/ml to about 40 ng/ml when the dosage form contains 100 mg metoprolol tartrate;
said dosage form providing a therapeutic effect for about 24 hours after oral administration.
- said oral dosage form providing a mean Cmax of metoprolol from about 10 ng/ml to about 40 ng/ml when the dosage form contains 100 mg metoprolol tartrate;
- 61. A method of preventing or reducing a mallaird-type reaction in a metoprolol tartrate sustained release oral dosage form comprising preparing said sustained release oral dosage form by combining a therapeutically effective amount of metoprolol tartrate with a sustained release excipient that provides for the sustained release of said metoprolol tartrate, and including in said dosage form an effective amount of mannitol to prevent or reduce the degradation of said metoprolol tartrate.
-
64. A method of preparing a sustained release tablet formulation of metoprolol tartrate for once-a-day administration comprising:
spray granulating a sustained release excipient and metoprolol tartrate with a suspension or solution comprising a cellulose derivative selected from the group consisting of an alkylcellulose, hydroxyalkylcellulose, hydroxyalkylalkylcellulose, or mixtures thereof; and
tableting the resultant granulation such that each tablet provides a dose of metoprolol tartrate sufficient to provide a therapeutic effect for about 24 hours after oral administration.- View Dependent Claims (65, 66)
-
67. A sustained release oral solid dosage form comprising:
-
a sustained release matrix comprising a therapeutically effective amount of metoprolol tartrate and a sustained release excipient;
said oral dosage form providing a mean Cmax of metoprolol from about 10 ng/ml to about 40 ng/ml per 100 mg metoprolol tartrate, said dosage form providing a therapeutic effect for about 24 hours after oral administration. - View Dependent Claims (69, 70, 71)
-
-
68. A method of treating a patient with hypertension comprising:
administering to said patient a sustained release oral dosage form comprising a sustained release matrix comprising a therapeutically effective amount of metoprolol tartrate and a sustained release excipient;
said oral dosage form providing a mean Cmax of metoprolol from about 10 ng/ml to about 40 ng/ml per 100 mg metoprolol tartrate;
said dosage form providing a therapeutic effect for about 24 hours after oral administration.
-
72. A sustained release oral solid dosage form comprising:
a sustained release matrix comprising a therapeutically effective amount of metoprolol tartrate and a sustained release excipient;
said oral dosage form providing a mean Cmax at steady state of metoprolol from about 5 ng/ml to about 30 ng/ml per 50 mg metoprolol tartrate, said dosage form providing a therapeutic effect for about 24 hours after oral administration.
-
73. A sustained release oral solid dosage form comprising:
-
a sustained release matrix comprising a therapeutically effective amount of metoprolol tartrate and a sustained release excipient;
said oral dosage form providing a mean Cmax at steady state of metoprolol from about 4 ng/ml to about 20 ng/ml per 25 mg metoprolol tartrate, said dosage form providing a therapeutic effect for about 24 hours after oral administration.
-
-
74. A sustained release tablet formulation comprising:
-
about 31% by weight of metoprolol tartrate;
about 45% by weight of a sustained release excipient comprising xanthan gum, locust bean gum, calcium sulfate dihydrate, and mannitol;
about 3% by weight hydroxypropylmethylcellulose;
about 4% by weight talc;
about 2% by weight sodium stearyl fumarate;
about 9 to about 12% by weight hydrophobic coating material; and
about 3% by weight of a color coating material;
said formulation providing for the sustained release of said metoprolol tartrate. - View Dependent Claims (75, 76)
-
-
77. A sustained release tablet formulation comprising:
-
about 32% by weight of metoprolol tartrate;
about 48% by weight of a sustained release excipient comprising xanthan gum, locust bean gum, calcium sulfate dihydrate, and mannitol;
about 4% by weight hydroxypropylmethylcellulose;
about 4% by weight talc;
about 2% by weight sodium stearyl fumarate;
about 8% by weight hydrophobic coating material; and
about 3% by weight of a color coating material;
said formulation providing for the sustained release of said metoprolol tartrate. - View Dependent Claims (78, 79)
-
Specification